Dear Sir/Madam,

Please find the enclosed galley proofs of your article. Below are instructions on how to help facilitate the timely publication of your article in ANTICANCER RESEARCH.

1. Please read, correct and return the proofs to the Editorial Office within 2-3 working days.

2. Proofs may be Faxed, e-mailed or returned by the fastest mail available. Delays in the return of your proofs may necessitate transferring your paper to a later issue of the journal.

3. While reviewing your manuscript, please be on the lookout for unintended changes in the meaning of the text through editorial corrections or language improvements.

4. With the exception of the above, corrections should be limited to typographical errors.

5. To promote our rapid publication policy, figures are not sent to authors unless alterations have been made through the editing process.

6. **Should you require extra reprints of your article, please order them now.** Reprints ordered at this time will reach you considerably faster than if ordered after the publication of your article.

7. For further information on your article (publication date, volume, page numbers etc.), please contact the Editorial Office by Fax/Tel: 0030-22950-53389, e-mail: journals@iiar-anticancer.org, or by sending a letter to the Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou - Kalamou Rd., Kapandriti, P.O.Box 22, Attiki 19014, Greece.

8. In all correspondence with us please provide your manuscript number, your complete postal address, telephone/fax numbers and e-mail address.

Thank you for taking the time to study these guidelines.

Yours,

J.G. Delinassios

Managing Editor

Enclosures
Novel Therapy for Malignant Pleural Mesothelioma Based on Anti-Energetic Effect: An Experimental Study Using 3-Bromopyruvate on Nude Mice

XIAODONG ZHANG1,5, EMILIE VARN1, MÉLANIE BRIAND1, STÉPHANE ALLOUCHE2, NATACHA HEUTTE1, LAURENT SCHWARTZ4, LAURENT POULAIN1 and PHILIPPE ICARD1,3

1Anticancer regional Study Group (EA 1772-Bioticla), Anticancer Center François BACLESSE, Caen; 2Biochemistry Laboratory and 3Thoracic and Cardio-Vascular Surgery Department, University Hospital Center of Caen; 4Ecole polytechnique, Saclay, France; 5Graduate School of Guangxi Medical University, Guangxi, China

Abstract. Background: Most cancer cells exhibit increased anaerobic glycolysis and use this metabolic pathway for the generation of ATP as a main source of energy. This impaired metabolism of glucose, leading to secretion of lactic acid even in the presence of oxygen, is named the “Warburg effect”. Because cancer cells are partly or mainly dependent on such a pathway to generate ATP, inhibition of glycolysis may slow down the proliferation or kill cells. Materials and Methods: The effect of 3-Bromopyruvate (3-BrPA) alone or associated to cisplatin on nude mice presenting intraperitoneal carcinomatosis developed after intraperitoneal injection of human mesothelioma cells (MSTO-211H) was investigated. Results: 3-BrPA significantly prolonged survival of animals. Combined with cisplatin, it demonstrated significant benefit on survival whereas cisplatin alone had no or mild effect. Conclusion: 3-BrPA may thus constitute an interesting novel anticancer drug that could be tested in humans.

The development of malignant mesothelioma is often associated with an occupational exposure to asbestos (1). Because this cancer is usually resistant to chemotherapy and radiotherapy, most of patients die within two years of diagnosis (2). Therefore, about 250,000 deaths are predicted throughout Western Europe in the next two decades (3).

Most cancer cells exhibit increased aerobic glycolysis and use this metabolic pathway for the generation of ATP as a main source of energy. This impaired metabolism of glucose, leading to secretion of lactic acid (even in the presence of oxygen) is a phenomenon first described by Otto Warburg, more than 50 years ago (4). The increased cellular uptake of glucose is nowadays used to visualize cancer tumours with positron emission tomography using 2-deoxy-2-18F-D-glucose (FDG). Because ATP generation through glycolysis is far less efficient than through mitochondrial oxidative phosphorylation (2 versus 36 ATP per glucose), cancer cells consume far more glucose than normal cells to maintain sufficient energy production for their active metabolism and proliferation.

Although the biochemical and molecular mechanisms of the “Warburg effect” are rather complex and can be multiple (adaptation to the hypoxic environment, direct effect of hypoxia inducible factor 1 alpha, mutation in oncogenes or alteration of proteins involved in signal transduction pathways as well as in energetic metabolism) (5-7), the metabolic consequences are quite similar: cancer cells are partly or mainly dependent on such a metabolic pathway to generate ATP. Consequently, the inhibition of glycolysis may slow down the proliferation of cancer cells or kill cells (8, 9). Moreover, this action could be very interesting to destroy the median and profound part of tumours where the hypoxic environment favour cells to switch to a high glycolytic activity.

3-Bromopyruvate (3-BrPA) is an analogue of pyruvate, a cytoplasmic and mitochondrial molecule that plays a key role in the energetic metabolism. It causes a depletion of ATP in cancer cells, and this effect is especially severe in cells with mitochondrial DNA deletion and respiration defects, leading to massive cell death (5-7). In two previous studies performed on tumour bearing rabbit and rat, 3-BrPA has demonstrated an anti-tumoral activity with a beneficial effect on survival (6, 10). Although the drug could interfere with all biochemical enzymes metabolising pyruvate (i.e.,
pyruvate dehydrogenase, pyruvate carboxylase, or lactate dehydrogenase), it has been considered to be able to inhibit hexokinase (HK), the first key enzyme of glycolysis (5). Moreover, HK is associated with phospho-Bad and VDAC to form a complex on the external mitochondrial membrane inhibiting apoptosis. It has been shown that the removal of HK by 3-BrPA from this complex allows Bad dephosphorylation and leads to apoptosis induction (11, 12). It is noteworthy that depletion of ATP by 3-BrPA also induces apoptosis in multi-drug resistant cells (7). Otherwise, it has been observed that severe depletion in ATP tends to cause cell death by necrosis rather than by apoptosis, especially in cells exhibiting a high glycolytic activity (hypoxic environment and/or respiratory mitochondrial dysfunction) (7, 8, 13).

The aim of this work was to report the effect of 3-BrPA, associated or not to conventional chemotherapy (cisplatin), in peritoneal carcinomatosis developed in nude mice after intra-peritoneal injection of human mesothelioma MSTO-211H cells.

Materials and Methods

Cell line and culture. Human mesothelioma cell lines MSTO-211H and NCI-H28 were obtained from the American Type Culture Collection (ATCC), USA. Cell lines were grown in RPMI 1640 medium supplemented with 2 mM Glutamax™ (Fisher Scientific Bioblock, Illkirch, France), 10% fetal calf serum (Fisher Scientific Bioblock), 20 mM HEPES and 33 mM sodium bicarbonate (Gibco BRL, Lyon, France). Cells were maintained in a 5% CO₂ humidified atmosphere at 37°C.

Nude mice. Five weeks old athymic female nude mice (Swiss/Nude CD1), weighing 20-25 g, were obtained from Charles River Laboratory (L’Abresles, France). Animals were kept under pathogen free conditions and given food and water ad libidum. When considered as moribund, animals were sacrificed, and laparotomy was performed to confirm the diffuse peritoneal carcinomatosis that was checked histologically to correspond to mesothelioma (Pr. François Galateau, Dr Cécile Blanc-Fournier). Experiments were conducted according to the national ethical committee.

Chemicals. The solution of 3-BrPA (Sigma Aldrich) was dissolved in 0.9% NaCl and neutralized by NaOH until pH 7.5. Cisplatin received both treatment: cisplatin at day 21 followed by four days of a dose of 4 mg/kg in 1 ml 0.9% NaCl and neutralized by NaOH until pH 7.5. Cisplatin received both treatment: cisplatin at day 21 followed by four days of dose of 4 mg/kg in 1 ml 0.9% NaCl; combined treated group received a single intraperitoneal injection of the drug at a dose of 2.67 mg/kg in 0.8 ml (i.e. 500 μM); cisplatin treated group received a single intraperitoneal injection of the drug at a dose of 4 mg/kg in 1 ml 0.9% NaCl; combined treated group received both treatment: cisplatin at day 21 followed by four days of treatment with 3-BrPA at the same aforementioned doses. The dose of 3-BrPA was chosen according to the publication of Ko et al. (6), whereas the dose of cisplatin (C4) was chosen after a study performed in our laboratory about the drug toxicity showing a renal toxicity at a dose of 8 mg/kg of cisplatin, and no anti-tumoral activity at a dose of 2 mg/kg. Therefore, the dose of 4 mg/kg (C4) appeared as a good compromise, non toxic with a relative efficiency. It is noteworthy that doses ranged from 3 to 6 mg/kg are commonly used by researchers using cisplatin in various laboratories.

In a first series of experiments, animals were pair-matched in several groups (12 mice per group) at day 21 as follows: control group received 1 ml of physiological serum; 3-BrPA treated group received a daily intraperitoneal injection of the drug during 4 days at a dose of 2.67 mg/kg in 0.8 ml (i.e. 500 μM); cisplatin treated group received a single intraperitoneal injection of the drug at a dose of 4 mg/kg in 1 ml 0.9% NaCl; combined treated group received both treatment: cisplatin at day 21 followed by four days of

Mitochondrial respiration. MSTO-211H and NCI-H28 cells were grown in 75 cm² flask until 80-90% of confluence. Cells were detached in 0.25% trypsin/EDTA solution, harvested by trypsinization, rinsed with phosphate-buffered saline (PBS) then suspended in the respiration buffer (KMES 100 mM, KH₂PO₄ 5 mM, EGTA 1 mM, EDTA 3 mM, BSA 1 mg/mL and ADP 1 mM, pH=7.4).

Oxygen consumption was measured at 37°C using the Hansatech polarograph in a final volume of 0.4 mL. Mitochondrial respiration was recorded after addition of digoxigenin 0.005%, rotenone 25 μM and succinate 25 mM. The reaction specificity was demonstrated using KCN 2.5 mM. Results shown are expressed as nmol of O₂/min/mL.

Statistical analysis. Survival was calculated in days according the Kaplan-Meier method and survivals were compared using the log-rank test (logiciel SAS 9.1), with a 95% confidence interval, and a p-value less than 0.05 was considered as significant.

Results

In the first experimentation (Figure 1A), survival of animals receiving 3-BrPA or cisplatin alone was not improved as compared to control animals. In these groups, almost all mice died before day 45. In contrast, animals treated by the association cisplatin/3-BrPA had a significant benefit on survival as compared both to control group (p=0.0021), or to groups receiving 3-BrPA alone (p=0.0024) or cisplatin alone (p=0.0161). This benefit was approximately 20 days as compared to the control, which accounts for about 30% of additional survival at day 45. It must be noticed that in this experiment, tumor did not developed in 10% of mice, even in the control group. Therefore, the results of autopsy of the animals that survived more than 80 days are difficult to interpret: two of three mice that were treated with 3-BrPA and C4 had no tumor. However, these results encouraged reproduction of this experimentation, but in order to increase the efficiency of this protocol, reiteration of the administration of 3-BrPA for four days one week after the end of the last injection was performed.

The results of this second experimentation are presented in Figure 1B. In contrast with the first experimentation,
cisplatin alone exerted this time a beneficial effect on survival \( (p=0.0329) \), but this effect was mild. Also, the reiteration of the administration of the 3-BrPA alone one week later produced a significant effect on survival of the treated animals when compared to control animals \( (p<0.001) \) or to animals that received only cisplatin \( (p=0.0012) \). Moreover, the association of cisplatin with 3-BrPA administered in such conditions (reiteration one week later) also demonstrated a very significant effect on survival when compared to the control group \( (p<0.0001) \). At 45 days, the survival rate of animals treated by associated treatments was 25% whereas all untreated animals died within 28 days. However, this association did not provide better survival than that observed with 3 BrPA alone. It is noteworthy that in this second experimentation where control animals demonstrated 100% of tumor development, two animals treated by 3 BrPA alone and two animals treated by 3 BrPA and C4 survived at day 50. Tumor development was then evaluated after sacrifice, showing that in mice treated with 3BrPA alone mild tumour development was observable in various areas of the abdominal cavity, whereas in mice treated with 3 BrPA and C4 no residual tumor remained observable.

**Discussion**

Because prognosis of human mesothelioma is very poor, experimental research aiming to define new therapeutics improving survival is needed. In this study, the therapeutic potential of 3-BrPA in a pertinent model of mesothelioma established in vivo was directly assessed, the goal being to evaluate the survival benefit. Both pleural and peritoneal mesothelioma models could be used for such investigation. Some authors have tried to establish human mesothelioma directly in the pleura of animals by injecting tumour cells (H-meso I cell line) in the pleural space of immunodeficient rats after a left pneumonectomy (14). Other authors have fixed fresh fragments of human tumours in the left pleural cavity of nude mice (15, 16). However, considering both the morbidity associated with such a pleural tumour implantation (risk of pneumothorax) and the difficulty to administer reiterated treatments through this way, experimental studies performed in vivo on mesothelioma are frequently realized on peritoneal carcinomatosis (17, 18). Thus, it was decided to develop a simpler model by injecting a human cancer cell line (MSTO-211H) in the abdominal cavity of nude mice. Moreover, it must be noticed that around 5% of mesothelioma develop first in the peritoneal cavity, and that secondary invasion of the peritoneum is a usual event during extension of pleural mesothelioma.

Because Pedersen and colleagues reported impressive results using 3-BrPA, either in Sprague-Dawley rats (6) or in rabbits (10) bearing human hepatocellular carcinoma (HCC) ("AS-30D" line), the efficiency of this drug in mesothelioma was investigated. Indeed, when 3-BrPA was administered over four days in rats presenting «advanced» subcutaneous or intraperitoneal tumours (2-3 cm in diameter), either by direct intratumoral injection or by intraperitoneal injection, a complete regression of tumours and prolonged survival was observed (6), sometimes after a sole injection of 3-BrPA (10). When the drug was administered intravenously, a markedly suppression of secondary metastatic tumors in the lung was observed, without harmful effects (10).

In this model of mesothelioma, it was not possible to reproduce such impressive results using 3-BrPA, but mainly a very significant prolongation of survival of treated animals, evocating only a slow down of tumor development. When 3-BrPA was used alone, tumor residues were systematically observed in mice surviving more than 45 days.

Moreover, this increase of survival was obtained only after reiterated treatment, since this effect was not observed in the first experiment in which 3-BrPA was only administered during four days. However, in such reiterated conditions, 3-BrPA appeared more active that conventional chemotherapy with cisplatin.

Although the adjunction of cisplatin to 3-BrPA did not significantly increase survival as compared to 3-BrPA alone in the second experiment, it must be noticed that two out of three animals who survived more than 45 days did not demonstrate any residual tumors. Therefore, the rate of complete response was 2/12 \( (i.e.: 17\%) \). These complete responses suggest that the association of cisplatin and 3-BrPA exerts a cytotoxic effect more important than that exerted by the drugs given separately. This is in agreement with the study reported by Xu et al. (7) suggesting that such an antiglycolytic strategy could help to overcome drug resistance. Such a synergy could be explained by various hypotheses. Indeed, 3-BrPA could have impeded DNA repair since ATP is needed for this reparation thus leading to a higher level of persistent DNA damages due to platination. Furthermore, as aforementioned 3-BrPA could allow Bad dephosphorylation (through its action on Hexokinase) thus favouring Bax/Bak induced apoptosis, these proteins being themselves activated by cisplatin (11, 12, 19, 20).

The difference of response to 3-BrPA alone between this study and the studies previously published (6, 10) could be due to differences in the level of mitochondrial respiration varying from one cell type to another. Moreover, among mesothelioma cells such differences were also observed. Indeed, in two human mesothelioma cell lines, great differences in the response to 3-BrPA were observed: it only slowed down the proliferation of MSTO-211H cells, whereas it efficiently killed NCI-H28 cells (Figure 2A). Investigating the mitochondrial respiration, it was observed that MSTO-211H cells exhibited a normal mitochondrial respiration, whereas NCI-H28 cells presented a clearly decreased mitochondrial respiration (Figure 2B). The distinct responses
Figure 1. Effect of 3-BrPA on mesothelioma bearing mice survival. [A]: Unique administration of 3-BrPA during 4 days; [B]: reiterated administration of 3-BrPA during 4 days one week after the first series of injections.
to 3-BrPA could be correlated to the different possibilities of cells to use their mitochondrial respiration and to overcome glycolytic inhibition. Further studies are needed to precise these points that suggest a level of Warburg effect variation depending of the type of cancer cells. It could be interesting to evaluate the effect of 3-BrPA on tumour developed in vivo by NCI-H28 mitochondrial respiration deficient cells, but unfortunately, for unexplained reasons, no abdominal carcinomatosis could be produced by injection of these cells in abdominal cavity of nude mice.

In summary, it was shown that 3-BrPA is able to slow-down tumor development of mesothelioma, and that its

Figure 2. Effect of 3-BrPA on MSTO-211H and NCI-H28 cell lines in vitro and study of mitochondrial respiration in these cell lines [A]: number of viable cells in the flask after three days of 3-BrPA exposure; [B]: oxygen consumption by MSTO-211H and NCI-H28 cells.
association with cisplatin may allow complete response, as observed in about 20% of mice. Moreover, this effect could be amplified in mitochondria deficient cells, as suggested by in vitro results and by Xu et al. (7). Finally, deprivation of cellular energy supplied by 3-BrPA could be a novel anticancer strategy that could be interesting to further evaluate and optimize the treatment of human mesothelioma, particularly as a neo-adjuvant treatment in association with conventional chemotherapy.

Acknowledgements

We thank Marie-Christine Bon for animal care and Edwige Lemoisson for helpful technical assistance. This work was supported by the Association «Coeur et Cancer de Cherbourg», the «Caisse d’Epargne Régionale de Basse-Normandie», and the «Ligue Contre le Cancer» (Comités de la Manche, de l’Orne et du Calvados).

References

Dr. Philippe Icard

Re: Your manuscript No. 9991-Z entitled «Novel Therapy for Malignant Pleural...»

Dear Dr. Icard,

Referring to your above manuscript for publication in AR, please allow us to use this form letter in reply:

1. **Referee’s recommendations:**
   - □ Urgent to be published immediately.
   - □ Accepted in the presented form.
   - □ Accepted with minor changes.
   - □ Accepted with grammatical or language corrections.
   - □ Remarks:

2. **Excess page charges.**
   - □ Your article has approx. 6 printed pages and is in excess of the allotted number by approx. 2 printed pages. The charges are EURO € 180 per excess page, totalling EURO € 360. We ask you to confirm acceptance of these charges.
   - □ Your article includes 2 pages with color figures. The charges are EURO € 650 per color page, totalling EURO € 1300. 
   - □ Total charges are EURO € 1660 (-20% Discount)
   - □ Our invoice is sent by air mail to the corresponding author.

3. □ Your article will appear in Volume 29, Issue No. 4, 2009

4. □ Please order your reprints now. This will facilitate our prompt planning of future issues and rapid publication of your article. Reprints will be delivered by air mail within one month from publication.

We would appreciate your prompt reply.
With many thanks,
Yours sincerely,

J.G. Delinassios
Managing Editor

EDITORIAL OFFICE: INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH
1st km Kapandritiou - Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece. Tel.: 0030-22950-52945; Tel & Fax:0030-22950-53389; e-mail: journals@iiar-anticancer.org
Please type or print the requested information on the reprint order form and return it to the Editorial Office by fax or e-mail.

Reprints must be paid for in advance.

If your paper is subject to charges for excess pages or color plates, please add these charges to the payment for reprints.

The reprints are not to be sold.

### PRICE LIST FOR REPRINTS WITHOUT COVER

<table>
<thead>
<tr>
<th>Page length</th>
<th>PDF file</th>
<th>100</th>
<th>200</th>
<th>300</th>
<th>400</th>
<th>500</th>
<th>1000</th>
<th>1500</th>
<th>2000</th>
<th>3000</th>
<th>5000</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-4pp</td>
<td>167</td>
<td>335</td>
<td>387</td>
<td>438</td>
<td>503</td>
<td>554</td>
<td>851</td>
<td>1135</td>
<td>1470</td>
<td>2038</td>
<td>3225</td>
</tr>
<tr>
<td>5-8</td>
<td>219</td>
<td>438</td>
<td>503</td>
<td>580</td>
<td>645</td>
<td>722</td>
<td>1083</td>
<td>1445</td>
<td>1832</td>
<td>2554</td>
<td>4012</td>
</tr>
<tr>
<td>9-12</td>
<td>277</td>
<td>554</td>
<td>619</td>
<td>709</td>
<td>787</td>
<td>877</td>
<td>1341</td>
<td>1780</td>
<td>2219</td>
<td>3096</td>
<td>4824</td>
</tr>
<tr>
<td>13-16</td>
<td>354</td>
<td>709</td>
<td>787</td>
<td>890</td>
<td>993</td>
<td>1096</td>
<td>1625</td>
<td>2141</td>
<td>2657</td>
<td>3676</td>
<td>5715</td>
</tr>
<tr>
<td>17-20</td>
<td>419</td>
<td>838</td>
<td>929</td>
<td>1032</td>
<td>1148</td>
<td>1277</td>
<td>1883</td>
<td>2451</td>
<td>3044</td>
<td>4244</td>
<td>6527</td>
</tr>
</tbody>
</table>

For reprints with cover: Please add EURO 140.00 per 100 copies.

Postage: Please add 4% on the above prices.

### Reprint Order Form

Of my paper No. **9991-Z** comprising **6** printed pages, entitled «*Novel Therapy for Malignant Pleural...*» accepted for publication in **ANTICANCER RESEARCH** Vol. **29** No. **4**

- [x] I require a total of **copies** at EURO
- [ ] I do not require reprints.
- [ ] Please send me a PDF file of the article at EURO.
- [ ] Please send me a copy of this issue containing my paper at EURO 45.00.
- [ ] Please enter my personal subscription to **ANTICANCER RESEARCH** at the special Author’s price of EURO 417.00 (print or online); EURO 500.00 (print & online) (☐ Year: 2009).
- [ ] A check for the above amounts payable to J.G. Delinassios, Executive Publisher of Anticancer Research Journal, is enclosed.
- [ ] Please send an invoice to:

For EC countries: Please give your VAT number: ____________________________

City and Date: ________________

Exact postal address: ____________________________

Tel: ____________________________

Fax: ____________________________

Signature: ____________________________